Respiratory Syncytial Virus or RSV cases are on the rise this holiday season. This week, Scientists from UW Medicine say they believe they have found the best candidate for a vaccine to treat the virus.

RSV can infect anyone and has no age restriction. The virus is especially dangerous to the elderly, and those with compromised immune systems. RSV can be dangerous to infants and young children as well. In countries with less medical resources, pneumonia from RSV is a major cause in infant mortality.

Now the University School of Medicine at UW is boasting Nano-Particle technology is the base for the best candidate of vaccines for the virus, and is currently undergoing human trials.

According to medical reports, the vaccine is a protein designed RSV vaccine, and has showed promise in phase one trials conducted in Seattle earlier this year.

Neil King, PHD, and Assistant Professor at the UW Institute for Protein Design says. "That vaccine is really, kind of marching forward in clinical development. We are hoping, if it's successful, we're hoping that it will be available in a very short time, maybe a couple of years."

The lab in the UW Institute for Protein Design are the pioneers of nanoparticle technology in vaccines, and formed into the basis for a Covid-19 vaccine that was approved for clinical use in South Korea, earlier this year.